Global Obesity Drugs and Companies Pipeline Review H2 2017

Summary

Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2530975-obesity-pipeline-review-h2-2017              

The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 16, 28, 125 and 27 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 57 and 13 molecules, respectively.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points

Table of Contents 2

Introduction 6

Obesity - Overview 7

Obesity - Therapeutics Development 8

Obesity - Therapeutics Assessment 36

Obesity - Companies Involved in Therapeutics Development 56

Obesity - Drug Profiles 98

Obesity - Dormant Projects 461

Obesity - Discontinued Products 476

Obesity - Product Development Milestones 480

…Continued                            

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2530975-obesity-pipeline-review-h2-2017                                            

Contact Info:                                                         

NORAH TRENT                                                      

[email protected]             

Ph: +1-646-845-9349 (US)                

Ph: +44 208 133 9349 (UK)                                                   

Get in touch:                                                         

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports                                                                  

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts   

Posted by Vivian Dsena on Monday November 27 2017, 5:04 AM EDT. All trademarks acknowledged. Filed under Uncategorized. Comments and Trackbacks closed. Follow responses: RSS 2.0